# US 2012/0070417 A1 · Anti-influenza formulations and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0070417 A1
- Document ID: US20120070417A1
- Status: Published application
- Kind: A1
- Application number: 13/259,659
- Filed: 2010-03-26
- Published: 2012-03-22
- Earliest claimed: 2009-03-26
- Assignees: Pulmatrix, Inc.
- Inventors: Richard Batycky; David L. Hava; Robert W. Clarke; Michal M. Lipp
- Web page: https://patentgrep.com/patent/US20120070417A1

## CPC

- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 31/125: Camphor; Nuclear substituted derivatives thereof
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.

## Claims

### Claim 1

A pharmaceutical composition comprising an effective amount of a calcium salt and an effective amount of an anti-influenza agent, wherein the anti-influenza agent is selected from the group consisting of an NAI, an M2 channel inhibitor, an IMP dehydrogenase inhibitor, an influenza RNA polymerase inhibitor, a sialidase, a sialidase fusion protein, a sialyl multimer or polymer, a siRNA that targets expression of influenza genes, an oligonucleotide that targets expression of influenza genes, interferon alpha, an interferon inducer, and a signal transduction inhibitor, and further wherein the composition is suitable for administration to the respiratory tract and the effective amount of the calcium salt and the effective amount of the anti-influenza agent are synergistic.

### Claim 2

(canceled)

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the anti-influenza agent is an NAI.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the NAI is selected from the group consisting of zanamivir, peramivir, oseltamivir phosphate, oseltamivir carboxylate and combinations thereof.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a liquid formulation.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the calcium salt is present in a concentration of from about 0.1% to about 20% (w/v).

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a dry powder.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the calcium salt is present in an amount of from about 30% to about 99% (w/w).

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises about 1 mg to about 20 mgs of NAI per dose.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1 further comprising a sodium salt.

### Claim at position 12

12-15. (canceled)

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated to provide an NAI dose of about 1 mg to about 20 mgs to the lungs.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method, comprising administering to an individual suspected of having influenza or at risk of having influenza an effective amount of a pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered to the respiratory tract.

### Claim 19 (depends on 1)

A method for treating influenza infection comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered to the respiratory tract.

### Claim 20 (depends on 1)

A method for the prophylaxis of influenza infection comprising administering to an individual at risk for infection by influenza virus an effective amount of a pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered to the respiratory tract.

### Claim 21 (depends on 1)

A method for reducing the spread of influenza infection comprising administering to an individual infected by influenza virus or at risk for infection by influenza virus an effective amount of a pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered to the respiratory tract.

### Claim at position 19

22-43. (canceled)

### Claim 44 (depends on 1)

The pharmaceutical composition of claim 1, where said anti-influenza agent is selected from the group consisting of a NAI, a sialidase and a sialidase fusion protein.

### Claim 45

(canceled)

### Claim 46 (depends on 20)

The method of claim 20, wherein said pharmaceutical composition comprises an anti-influenza agent selected from the group consisting of a NAI, a sialidase, a sialidase fusion protein and combinations thereof.

### Claim at position 23

47-50. (canceled)

### Claim 51

A method for treating influenza-like illness comprising administering to an individual in need thereof an effective amount of a calcium salt formulation.

### Claim 52

A method for the prophylaxis of influenza-like illness comprising administering to an individual at risk for infection by influenza-like illness an effective amount of a calcium salt formulation, wherein the calcium salt composition is administered to the respiratory tract.

### Claim at position 26

53-54. (canceled)
